New and exciting clinical data on evaxion's ai-immunology™-based personalized cancer vaccines to be presented

Copenhagen, denmark, oct. 26, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™-powered vaccines, is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at sitc's 38th annual meeting, taking place in san diego, california from november 1-5, 2023.
EVAX Ratings Summary
EVAX Quant Ranking